TABLE 3

Height of primary ciliary dyskinesia (PCD) patients of the iPCD Cohort compared to national height references by characteristics of the study population

CharacteristicsSubjects#z-scorep-value
Sex0.072
 Male774−0.22 (−0.30 to −0.13)
 Female827−0.32 (−0.40 to −0.24)
Age group years+<0.001
 0–9683−0.27 (−0.33 to −0.21)
 10–19683−0.31 (−0.37 to −0.25)
 20–29199−0.22 (−0.29 to −0.14)
 30–39119−0.20 (−0.29 to −0.11)
 40–4989−0.22 (−0.32 to −0.12)
 >5079−0.23 (−0.35 to −0.11)
Country§<0.001
 Australia55−0.31 (−0.60 to −0.01)
 Belgium79−0.66 (−0.92 to −0.40)
 Cyprus30−0.14 (−0.53 to 0.26)
 Denmark91−0.36 (−0.59 to −0.14)
 France1190.18 (−0.03 to 0.39)
 Germany94−0.76 (−0.99 to −0.53)
 Israel142−0.50 (−0.70 to −0.31)
 Italy38−0.41 (−0.77 to −0.06)
 Netherlands66−0.18 (−0.45 to 0.09)
 Norway22−0.64 (−1.10 to −0.17)
 Poland97−0.22 (−0.46 to 0.02)
 Switzerland47−0.01 (−0.32 to 0.29)
 Turkey30−1.09 (−1.51 to −0.66)
 UK277−0.15 (−0.29 to −0.01)
 USA/Canada414−0.16 (−0.30 to −0.05)
Diagnostic certainty0.897
 Definite PCD diagnosisƒ1054−0.28 (−0.35 to −0.21)
 Probable PCD diagnosis##254−0.27 (−0.42 to −0.12)
 Clinical diagnosis only293−0.24 (−0.37 to −0.10)

Data is presented as n or mean (95% CI) unless otherwise stated. Mean z-scores and 95% CI for each group were derived after adjusting for the remaining characteristics. #: total number of subjects (N) was 1601. : likelihood ratio test p-value indicating whether the characteristic explains differences in height within the study population. +: age at measurement (numbers represent the unique number of patients in each group, however, patients can be included in more than one group). §: patients from Serbia were excluded from this analysis because no national references were available. ƒ: defined as hallmark PCD electron microscopy findings and/or biallelic gene mutation, identified based on the ERS PCD Diagnostics Task Force guidelines. ##: abnormal light or high frequency video microscopy finding and/or low nasal NO value.